Walleye Capital LLC Invests $4.94 Million in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Walleye Capital LLC purchased a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the third quarter, according to its most recent filing with the SEC. The firm purchased 248,288 shares of the biopharmaceutical company's stock, valued at approximately $4,936,000. Walleye Capital LLC owned 0.21% of Catalyst Pharmaceuticals at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the 2nd quarter worth $258,000. Integral Health Asset Management LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the 2nd quarter worth $4,260,000. GSA Capital Partners LLP acquired a new stake in Catalyst Pharmaceuticals during the 3rd quarter worth about $625,000. Allspring Global Investments Holdings LLC lifted its position in Catalyst Pharmaceuticals by 146.8% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 366,444 shares of the biopharmaceutical company's stock worth $7,285,000 after acquiring an additional 217,956 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in Catalyst Pharmaceuticals by 9.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,000,756 shares of the biopharmaceutical company's stock worth $46,479,000 after acquiring an additional 263,099 shares during the period. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

CPRX has been the subject of a number of recent research reports. Stephens initiated coverage on Catalyst Pharmaceuticals in a research note on Monday, November 18th. They set an "overweight" rating and a $35.00 price objective for the company. HC Wainwright reiterated a "buy" rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, November 8th. Truist Financial upped their price target on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a "buy" rating in a research note on Monday, November 11th. StockNews.com raised Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, August 9th. Finally, Citigroup upped their price objective on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a "buy" rating in a research note on Friday, August 9th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Catalyst Pharmaceuticals presently has a consensus rating of "Buy" and an average price target of $31.14.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ:CPRX traded up $0.46 during trading on Monday, reaching $22.53. 1,096,556 shares of the company's stock traded hands, compared to its average volume of 1,186,761. The company has a 50 day moving average of $21.26 and a 200-day moving average of $18.79. The stock has a market capitalization of $2.69 billion, a P/E ratio of 18.70, a price-to-earnings-growth ratio of 3.40 and a beta of 0.75. Catalyst Pharmaceuticals, Inc. has a 12 month low of $13.00 and a 12 month high of $24.27.

Insider Activity at Catalyst Pharmaceuticals

In related news, insider Gary Ingenito sold 12,000 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total transaction of $272,640.00. Following the completion of the transaction, the insider now directly owns 51,391 shares of the company's stock, valued at $1,167,603.52. This trade represents a 18.93 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Molly Harper sold 17,500 shares of the business's stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total transaction of $385,000.00. The disclosure for this sale can be found here. Company insiders own 11.00% of the company's stock.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.